Despite numerous attempts and clinical trials, cancer vaccines in humans have not proven to be effective. The reason for this is a simple one: humans do not react immunologically to their own body proteins, and most tumor proteins -- these would be the key components of a cancer vaccine -- are normal body proteins produced in abnormal amounts. In short, they are ineffective because they do not provoke strong immune responses.

To solve this problem, TPIMS' vast combinatorial peptide libraries mimic tumor protein fragments that, when tested as vaccines, provoke far stronger immune responses capable of curing cancer in experimental systems.

This proprietary technology is applied to the human condition and is especially useful for the treatment of prostate, breast, lung cancers and melanoma. This program is highly effective in identifying the key components of cancer vaccines over relatively short periods of time.

The potential outcomes of this research program in terms of human health and economics are enormous. Dr. Wilson's laboratory is conducting this research.

<< Melanoma | Wasting Syndrome (Cachexia) >>